All GLG News Analyses Filed Under: Cardiology

This product replaces Flonase. It not not the same molecule and it has an eye indication. Its market share in the US is hampered by its Tier 3 status. It should do better in the European market.

It has been used for many years (Diovan is the brand name.)

The devil is in the details! Far from disappointing, the protocol ammendments (dosing) based on pharmacokinetic analysis that have been effected are both prudent and reassuring. Prasugrel dosing is likely being adjusted to reflect its metabolism in various patient populations including the elderly and...

There is no reason to believe that prasugrel will be coming any time soon.  While Dr. Ware may not have given the reasons for the suspension of the trials, the only reason to stop enrollment in a study  of healthy volunteers is safety, as there is no efficacy end point. The only safety endpoint...

The news has drawn attention to the effectiveness of Avamys, the only prescription nasal steroid spray to achieve consistent results in all clinical trials. The report published in the Medical News Today (www.medicalnewstoday.com) is a confirmation from the GlaxoSmithKline plc about getting...

In terms of specific drugs, this is not a major change in the armamentarium available for treatment of allergic rhinitis/conjunctivitis.   

This is the European equivalent of Veramyst.  The control of ocular symptoms is a major marketing push but raises a few questions.  There are concerns regarding cataract formation with the higher potency steroid molecules.  Although low bioavailability is shown, there must be some direct...

The relieve of eye symptoms is an advantage, but a lot of doctors who treat patients suffering from allergic rhinoconjunctivitis choose antihistamines for them. If it´is really easier to use, it will meet the patients needs, a very important item for compliance with long-term treatments

From the standpoint of what is clinically practical, Avamys is not a new drug: it is fluticasone in a nasal spray, available for years as Flonase, now off patent and available in the U.S. generically and as Veramyst (the same product as Avamys). Despite claims that Avamys/Veramyst is the first drug...

Separation of brain effects from stem cell proliferative effect is plausible. However, the establishment of efficacy in stroke models has not been very predictive in the past.